Luxshare Precision Industry (02475): Partial exercise of the over-allotment option, price stabilization actions, and completion of the price stabilization period.
Luxshare Precision (02475) announced that the over-allotment option described in the prospectus was partially exercised by the overall coordinator (on its own and on behalf of the international underwriters) on August 5, 2026 (Wednesday), involving a total of 12,541,900 H shares (over-allotted shares), which accounts for approximately 3.27% of the total number of shares initially available for subscription under the global offering before any exercise of the over-allotment option. The over-allotted shares will be issued and allocated by the company at a price of HK$63.28 per H share.
Luxshare Precision Industry (02475) announced that the overall coordinator (on its own behalf and on behalf of international underwriters) has partially exercised the over-allotment option described in the prospectus on August 5, 2026 (Wednesday), involving a total of 12,541,900 H-shares (over-allotment shares), accounting for approximately 3.27% of the total number of sale shares initially available for subscription under the global offering before any over-allotment option is exercised. The over-allotment shares will be issued and allotted by the company at a price of HKD 63.28 per H-share.
The Listing Committee of the Stock Exchange has approved the listing and trading of the over-allotment shares. It is expected that the over-allotment shares will commence trading on the main board of the Stock Exchange at 9:00 am on August 10, 2026 (Monday).
In accordance with Section 9(2) of the Securities and Futures (Stabilizing Prices) Rules, Chapter 571W of the laws of Hong Kong, the company announces that the stabilization period relevant to the global offering ended on August 5, 2026 (Wednesday), which is the 30th day after the closing date for receipt of applications for the Hong Kong public offering. The stabilization actions taken by Goldman Sachs (Asia) L.L.C. or any of its affiliates or persons acting on its behalf during the stabilization period are as follows:
(i) A total of 57,520,900 H-shares were over-allocated in the international offering, accounting for approximately 15% of the total number of sale shares initially available for subscription under the global offering before any over-allotment option is exercised;
(ii) During the stabilization period, a total of 44,979,000 H-shares were continuously purchased in the market at prices ranging from HKD 50.95 to HKD 63.25 per H-share, accounting for approximately 11.73% of the total number of sale shares available for subscription under the global offering before any over-allotment option is exercised. The last purchase by the stabilizing agent or any of its affiliates or persons acting on its behalf in the market during the stabilization period was made on July 31, 2026, at a price of HKD 55.70 per H-share; and
(iii) The overall coordinator (on its own behalf and on behalf of international underwriters) partially exercised the over-allotment option on August 5, 2026 (Wednesday) at a price of HKD 63.28 per H-share, involving a total of 12,541,900 H-shares (accounting for approximately 3.27% of the total number of sale shares initially available for subscription under the global offering before any over-allotment option is exercised), to facilitate the delivery of part of the H-shares to the applicants who agreed to defer the delivery of their relevant H-shares subscribed under the global offering.
The portion of the over-allotment option that has not been exercised by the overall coordinator (on its own behalf and on behalf of international underwriters) has lapsed on August 5, 2026 (Wednesday).
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





